Filgrastim: Research, Dosing, and Where to Buy in 2026
A research-first profile for Filgrastim (G-CSF analog, granulocyte colony-stimulating factor analog), aggregating mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature without presenting medical guidance.
Filgrastim is a research compound profiled here from named-expert transcripts and peer-reviewed literature, without medical guidance. As of July 2026, The Peptide Wiki aggregates 8 PubMed-cited papers for Filgrastim, each linked to its source.
- Also indexed as G-CSF analog, granulocyte colony-stimulating factor analog.
- 0 aggregated dosing-protocol mentions from source transcripts.
- 8 PubMed-indexed citations listed in the research table below.
- 0 vendor recommendations captured from named experts.
What is Filgrastim?
Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.
Filgrastim Dosing Protocols
The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.
No transcript-derived dosing mentions in current source set.
Where to Buy Filgrastim in 2026
No tracked vendor recommendations for Filgrastim yet. See our vendor directory.
Side Effects and Safety
Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.
User Reviews
User reviews aggregator coming Q3 2026 (Reddit + YouTube comments + Discord research notes). Until then, see the expert quote section above and PubMed citations below.
Research Efficacy Snapshot
Published efficacy percentages cited in PubMed trials and named-expert reports about Filgrastim. Each line links to the original source.
- "Filgrastim was administered by physician discretion to seven patients (31.8%), and the median duration of neutropenia after lymphodepleting therapy was significantly shorter for those patients who received filgrastim (5 vs 15 days, P = .016)." · Gaut D et al, 2021 PubMed
- "Five patients (22.7%) developed infection in the 30 days post-CAR T-cell therapy with three patients being Grade 3 or higher." · Gaut D et al, 2021 PubMed
- "Among the seven patients that received filgrastim, six patients (85.7%) and four patients (57.1%) had evidence of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), respectively." · Gaut D et al, 2021 PubMed
- "Among the 15 patients that did not receive filgrastim, 8 patients (53.3%) and 7 patients (46.7%) had evidence of CRS and ICANS, respectively." · Gaut D et al, 2021 PubMed
- "However, more recent meta-analyses of placebo-controlled randomized trial data show falling costs due to biosimilar competition and absolute overall survival gains of 3.2% (95% CI: 2.1-4.2%) from filgrastim support of cytotoxic chemotherapy." · Cornes P et al, 2019 PubMed
Research and Studies
8 PubMed-indexed papers reference Filgrastim. Top 8 shown.
Legal Status
Filgrastim is presented here as a research compound. FDA approval status, scheduling, WADA status, and state-specific telehealth rules may apply. Always verify current regulatory status. Last verified: 2026-07-09.
Frequently Asked Questions
Is Filgrastim FDA-approved?
Filgrastim is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.
How much research has been published on Filgrastim?
8 PubMed-indexed paper(s) reference Filgrastim in our current research feed. See the Research and Studies section above for citations.